The Medical Letter - 2017
Year:    Publication:     
November 20, 2017 (Issue 1534)  
November 6, 2017 (Issue 1533)  
October 23, 2017 (Issue 1532)  
  • Drugs for Common Bacterial Infections in Adults
    Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and...
  • Tisagenlecleucel (Kymriah) for ALL
    The FDA has approved tisagenlecleucel (Kymriah — Novartis), an individualized, genetically-modified cellular product, for treatment of relapsed or refractory B-cell precursor acute...
  • Correction
    In our article on Drugs for Cognitive Loss and Dementia (Med Lett Drugs Ther 2017; 59:155), the last sentence at the end of the article should have been omitted. It has been deleted from the...
  • Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer (online only)
    The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line...
October 9, 2017 (Issue 1531)  
September 25, 2017 (Issue 1530)  
September 11, 2017 (Issue 1529)  
August 28, 2017 (Issue 1528)  
August 14, 2017 (Issue 1527)  
July 31, 2017 (Issue 1526)  
July 17, 2017 (Issue 1525)  
July 3, 2017 (Issue 1524)  
  • Drugs for Sexually Transmitted Infections
    The text and tables that follow include recommendations for management of sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages...
June 19, 2017 (Issue 1523)  
June 5, 2017 (Issue 1522)  
May 22, 2017 (Issue 1521)  
May 8, 2017 (Issue 1520)  
April 24, 2017 (Issue 1519)  
April 10, 2017 (Issue 1518)  
March 27, 2017 (Issue 1517)  
March 13, 2017 (Issue 1516)  
  • Drugs for Hypertension
    in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
February 27, 2017 (Issue 1515)  
February 13, 2017 (Issue 1514)  
January 30, 2017 (Issue 1513)  
January 16, 2017 (Issue 1512)  
  • Drugs for Type 2 Diabetes
    The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C...
January 2, 2017 (Issue 1511)  
  • Antiviral Drugs for Seasonal Influenza 2016-2017
    Antiviral drugs can be used for prophylaxis and treatment of influenza. Frequently updated information on influenza activity, testing for influenza, and antiviral resistance is available from the...
  • Another Insulin Glargine (Basaglar) for Diabetes
    The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300...
  • Ustekinumab (Stelara) for Crohn's Disease
    The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab (Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who...
  • Tenofovir Alafenamide (Vemlidy) for Hepatitis B
    The FDA has approved tenofovir alafenamide (Vemlidy – Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first...